相关临床试验
4
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
50.0%
已完成
1
25.0%
招募中
1
25.0%
暂无批准数据
- Monte Rosa Therapeutics received a $50 million milestone payment from Novartis after the first patient was dosed in a Phase 2 trial of MRT-6160 in Sjögren's disease. - MRT-6160 (DDY391) is an oral molecular glue degrader of VAV1 that achieved over 90% target degradation in a Phase 1 study without serious adverse effects. - The Novartis agreement includes up to $2.1 billion in development, regulatory and sales milestones, with Novartis funding all Phase 2 studies. - Monte Rosa reported a second-quarter 2026 net loss of $43.4 million and $626 million in cash, which management says funds operations into 2029.
- Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing an 85% reduction in high-sensitivity C-reactive protein (hsCRP) after four weeks of treatment in subjects with elevated cardiovascular disease risk. - The molecular glue degrader achieved rapid and sustained degradation of NEK7 protein (80-90%) and significantly reduced inflammatory markers including IL-6 levels by 55% to below cardiovascular risk thresholds. - The company plans to expand the GFORCE-1 study and initiate Phase 2 trials in atherosclerotic cardiovascular disease in 2026, while also evaluating the drug for additional inflammatory conditions including MASH, gout, and recurrent pericarditis.
- Monte Rosa Therapeutics unveiled preclinical data showing MRT-8102 effectively blocks the NLRP3 inflammasome and reduces inflammatory cytokines linked to cardiovascular disease at the American Heart Association's 2025 Scientific Sessions. - The company is set to present updated Phase 1/2 clinical results for MRT-2359 in metastatic castration-resistant prostate cancer patients on December 16, 2025. - Monte Rosa strengthened its financial position with $396.2 million in cash as of September 2025, supported by a $120 million upfront payment from Novartis and sufficient funding projected through 2028.
- Novartis raised its compound annual sales growth forecast to 5-6% from 2025 to 2030, driven by eight commercialized assets with multi-billion dollar potential including Kisqali and Scemblix. - The company increased peak sales projections for key drugs, with Kisqali now expected to exceed $10 billion and Scemblix raised to over $4 billion from previous estimates. - Novartis achieved core operating margins of 41.2% in the first nine months of 2025, two years ahead of schedule, with expectations to maintain above 40% margins beginning in 2029. - The pharmaceutical giant completed over $23 billion in strategic acquisitions in 2025, including Avidity Biosciences for $12 billion, while maintaining its dual M&A strategy targeting both early-stage and near-launch assets.
- Monte Rosa Therapeutics published groundbreaking research on the cover of Science magazine, demonstrating how their AI and machine learning technologies have dramatically expanded the targetable protein space for molecular glue degraders. - The company's proprietary QuEEN discovery engine identified over 100 classes of proteins previously considered undruggable, spanning diverse therapeutic areas including immunology, inflammation, and oncology. - The research reveals new rules governing cereblon-based protein degradation, enabling rational design of highly selective degrader therapies for historically intractable therapeutic targets.
- Monte Rosa Therapeutics received FDA clearance for its Investigational New Drug application for MRT-8102, a NEK7-directed molecular glue degrader targeting inflammatory diseases driven by NLRP3 inflammasome and IL-1β dysregulation. - MRT-8102 demonstrated nanomolar-level NEK7 degradation with no off-target activity and achieved near-complete inhibition of downstream inflammatory markers in non-human primate studies. - The company plans to initiate a Phase 1 healthy volunteer study in the coming weeks, with clinical results including safety, pharmacokinetics, and pharmacodynamic data expected in the first half of 2026. - Preclinical toxicology studies showed a greater than 200-fold exposure margin over the projected human efficacious dose, supporting MRT-8102's potential safety profile for clinical development.
- Monte Rosa Therapeutics presented preclinical data at AACR 2025 showing their CDK2-directed molecular glue degrader MRT-51443 achieved superior tumor regression compared to standard care in HR-positive/HER2-negative breast cancer models. - The combination of MRT-51443 with CDK4/6 inhibitor and anti-estrogen therapy demonstrated median tumor growth of -77% versus -3% for standard care in MCF7 models. - MRT-51443 showed highly selective CDK2 degradation with no detectable off-target activity and delayed resistance to CDK4/6 inhibition in vitro studies. - The company anticipates submitting an IND application for their cell cycle program in 2026, potentially offering improved treatment for patients who develop resistance to current therapies.
- Roche has signed a $2 billion partnership with Monte Rosa Therapeutics, including a $50 million upfront payment, to develop molecular glue therapies targeting previously "undruggable" proteins in cancer and neurological diseases. - This marks Roche's second major molecular glue deal in a month, following a similar $2 billion alliance with Orionis Biosciences, demonstrating the company's strategic push to establish leadership in this emerging therapeutic category. - Monte Rosa will lead discovery and preclinical activities using its QuEEN platform, with Roche taking over late-stage development of candidates that can potentially address the 80% of human proteins currently inaccessible to traditional drug development approaches.
• Monte Rosa Therapeutics anticipates Q1 2025 clinical data from its Phase 1 study of MRT-6160, a VAV1-directed molecular glue degrader for immune-mediated conditions. • The company expects to share additional Phase 1/2 results for MRT-2359 in Q1 2025, which targets MYC-driven solid tumors and has shown a favorable safety profile. • An IND application for MRT-8102, a NEK7-directed molecular glue degrader for inflammatory diseases, is on track for submission in the first half of 2025. • Monte Rosa's strong cash position, with $377 million expected as of December 31, 2024, is projected to fund operations into 2028.
• The NLRP3 protein inhibitors pipeline is robust, with over 20 companies developing more than 25 inhibitors targeting various inflammatory conditions. • NLRP3 inhibitors are being explored for treating neurodegenerative diseases like Alzheimer’s and Parkinson’s, as well as metabolic conditions such as NASH. • Clinical trials are underway, with companies like Novo Nordisk and NodThera reporting positive data on their NLRP3 inhibitor candidates. • Collaborations, such as the one between Halia Therapeutics and Biolexis Therapeutics, are advancing the development of brain-penetrant NLRP3 inhibitors for neuroinflammation.
